{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.3344","value":"23.351"},{"groupId":"OG001","spread":"7.9960","value":"24.526"}]}],"title":"Pre-infusion - dose (Cmin) (n: 73, 57)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.8549","value":"64.279"},{"groupId":"OG001","spread":"15.5198","value":"60.576"}]}],"title":"End of infusion (Cmax) (n: 75, 59)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"59"}],"units":"Participants"}],"description":"Pre-infusion (Cmin) and end of infusion (C2h) trastuzumab PK blood samples were collected at Cycle 3 Day 1. Only valid trastuzumab PK blood samples collected at steady state were used in the analyses.","dispersionType":"Standard Deviation","groups":[{"description":"Oral everolimus of 5 mg/day","id":"OG000","title":"Everolimus"},{"description":"Oral placebo everolimus of 5 mg/day","id":"OG001","title":"Everolimus Placebo"}],"paramType":"MEAN","populationDescription":"The Safety Set consisted of all patients who received at least one dose of the study treatment and who had at least one valid post-baseline safety assessment.","reportingStatus":"POSTED","timeFrame":"Cycle 3, Day 1","title":"Trastuzumab Blood Concentrations by Leading Dose and Time Point","type":"SECONDARY","unitOfMeasure":"ng/ml"}